Abstracts Archive - Page 461 of 2425 - ACR Meeting Abstracts

Abstract Number: 2027 • ACR Convergence 2022
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Uzma Nakshbandi¹, Martha S. van Ginkel¹, Silvia Liefers², Hendrika Bootsma², Fred Spijkervet², Arjan Vissink¹, Bert van der Vegt¹ and Frans Kroese², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
Abstract Number: 2029 • ACR Convergence 2022
Distinctive Clinical Profiles Associated with anti-SSA/Ro60, anti-Ro52/TRIM21 and Anti-SSB/La Reactivity
Liselotte Deroo¹, Helena Achten², Kristel De Boeck², Eva Genbrugge², Wouter Bauters², Dimitri Roels², Frederick Dochy², David Creytens², Filip Van den bosch³, Dirk Elewaut⁴ and isabelle peene⁵, ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent, Belgium, ³Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁴Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium, ⁵Ghent University Hospital, Ghent, Belgium
Background/Purpose: Presence of anti-SSA/Ro antibodies is one of the 2016 ACR-EULAR classification criteria for primary Sjögren's Syndrome (pSS). Anti-SSA/Ro antibodies comprise reactivity against Ro52 and/or…
Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 2024 • ACR Convergence 2022
Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
Silvia Fonzetti¹, Francesco Ferro², Gaetano La Rocca³, Giovanni Fulvio⁴, Inmaculada Concepción Navarro García⁵, Gianmaria Governato⁶, Valentina Donati⁷, Marta Mosca⁸ and Chiara Baldini⁴, ¹Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Palermo, Palermo, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁶Azienda Ospedaliera Universitaria Pisana, Pisa, Pisa, Italy, ⁷Pathology Unit, University of Pisa, Pisa, Italy, ⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Salivary gland ultrasound (SGUS) abnormalities have been increasingly recognized as possible biomarkers for Sjögren's Syndrome (SS) phenotypic stratification. However, to date few studies have…
Abstract Number: 2028 • ACR Convergence 2022
The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
Martha S. van Ginkel¹, Andor WJM Glaudemans¹, Bert van der Vegt¹, Arjan Vissink¹, Frans Kroese² and Hendrika Bootsma², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Jonathan Hubbard¹, Kim Campbell¹, Kathy Sivils¹, Robert Hoffman¹, Kim Hung Lo¹, Jocelyn Leu¹, Sophia Liva¹, Qing Zuraw¹, Anne Stevens¹, Leona Ling², Keith Karcher³, Sindhu Ramchandren³, Hong Sun³, Hal Scofield⁴, Daniel Wallace⁵ and Raphaèle Seror⁶, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Cambridge, MA, ³Janssen Research & Development, LLC, Titusville, NJ, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: 1991 • ACR Convergence 2022
Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
Siba Raychaudhuri¹, Smriti Raychaudhuri² and Heike Wulff³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²VA Medical Center, Sacramento, CA, ³UC Davis, Davis, CA
Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1.…
Abstract Number: 2016 • ACR Convergence 2022
Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Abelina Schneider³, Anne Pankow³, Linda Hartman⁴, Jose Pereira da Silva⁵, John Kirwan⁶, Siegfried Wassenberg⁷, Christian Dejaco⁸, Robin Christensen⁹, Maarten Boers¹⁰ and Frank Buttgereit¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, ⁵University of Coimbra, Rheumatology, Columbia, Portugal, ⁶University of Bristol, Bristol, United Kingdom, ⁷Rheumazentrum Ratingen, Ratingen, Germany, ⁸Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
Abstract Number: 1990 • ACR Convergence 2022
Artificial Intelligence Applied to Transcriptomics Profiling of Synovial Tissue Biopsies Accurately Predicts Rheumatoid Arthritis Patients Who Will Respond or Be Refractory to Standard Biological Treatments
Giorgio CASABURI, Todd Holscher and Ming-Chou Lee, Exagen, Inc., Vista, CA
Background/Purpose: In recent years, biological therapies have revolutionized treatments of Rheumatoid Arthritis (RA). However, about 40% of RA patients do not respond to given biologics…
Abstract Number: 1589 • ACR Convergence 2022
Multiple Switching Between the Biosimilar Adalimumab PF-06410293 (Abrilada™) and Reference Adalimumab (Humira®)in Combination with Methotrexate in Patients with Moderately to Severely Active Rheumatoid Arthritis
Roy Fleischmann¹, Sharad Lakhanpal², WASSIM Saikali³, Daniel Alvarez⁴, Donna S Cox⁴, Claudia Ianos⁵, Karen Wang⁶ and Wuyan Zhang⁷, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³Rheumatology and Pulmonary Clinic, Beckley, WV, ⁴Pfizer, Inc, Collegeville, PA, ⁵Pfizer Zürich, Zürich, Switzerland, ⁶Pfizer, Inc, La Jolla, CA, ⁷Pfizer, Inc, Lake Forest, IL
Background/Purpose: PF-06410293 (ADL-afzb) is an adalimumab (ADL) biosimilar approved in the US, the EU, and 19 other countries. Biosimilarity of ADL-afzb with reference ADL (ADL-REF)…
Abstract Number: 1594 • ACR Convergence 2022
Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus
Yiran Jiang¹, Ali Duarte-Garcia², Mike Putman³ and David Gazeley⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³The Medical College of Wisconsin, Milwaukee, WI, ⁴Medical College of Wisconsin, Wauwatosa, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect patients receiving immunosuppression. There are no consensus guidelines for PJP prophylaxis among patients…
Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Sofie Falkenløve Madsen¹, Dovile Sinkeviciute², Christian Thudium², Morten Karsdal² and Anne-Christine Bay-Jensen², ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
Abstract Number: 2023 • ACR Convergence 2022
Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms
Martha Tsaliki¹, Joshua Cavett¹, Biji T. Kurien², Christina Bruxvoort¹, Robert Hal Scofield² and Kristi A Koelsch³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s Syndrome (SS) diagnosis depends on clinic examinations that involve measurements of serum levels of anti-Ro\SSA, anti-La\SSB, and rheumatoid factor antibodies; the first is…
Abstract Number: 1599 • ACR Convergence 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Joseph Merola¹, Robert Landewé², Iain B McInnes³, Philip J Mease⁴, Christopher Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Richard Warren¹¹, Barbara Ink¹², Deepak Assudani¹², Rajan Bajracharya¹², Jason Coarse¹³ and Laura Coates¹⁴, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Sorbonne Université, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].